Cardiovascular Risk Combination Basal Insulin GLP 1RA Therapy

Visit for the entire activity and to claim CE/CME credit.

The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes

In the activity, John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM). Based upon the pathophysiologic rationale for combining basal insulin and a GLP-1RA, Drs. Anderson and Fonseca discuss the benefits and limitations of adding a GLP-1RA vs prandial insulin in patients with inadequate glycemic control with basal insulin.